Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.87 USD

113.87
29,519,707

-1.57 (-1.36%)

Updated Jun 18, 2026 04:02 PM ET

After-Market: $114.10 +0.23 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 247)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study

by Zacks Equity Research

MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.

Kinjel Shah headshot

J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B

by Kinjel Shah

J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.

Kanishka Das headshot

MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026

by Kanishka Das

Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.

Kinjel Shah headshot

MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?

by Kinjel Shah

Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.

Zacks Equity Research

Here's Why Merck (MRK) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Aparajita Dutta headshot

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

by Aparajita Dutta

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Mark Vickery headshot

Pulling Back for a Fresh Look at This Recent Pullback

by Mark Vickery

Fed members are openly having second thoughts about further cuts to interest rates, especially with no new data on the jobs or inflation front.

Ekta Bagri headshot

BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?

by Ekta Bagri

Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.

Zacks Equity Research

Stock Market News for Nov 12, 2025

by Zacks Equity Research

Wall Street closed mixed on Tuesday, pulled up by healthcare, energy and consumer stocks.

Kanishka Das headshot

Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?

by Kanishka Das

Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.